Company news
Beijing Biostar Pharmaceuticals Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
November 3, 2026
Voluntary announcement - UTD2 of biostar achieves first patient dosing in phase iii clinical study for HER2-negative advanced breast cancer
October 20, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
October 7, 2026
Interim Report 2026
September 22, 2026
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
December 15, 2025
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
September 25, 2025
Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
September 15, 2025